Arthur F. Ryan Sells 100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Regeneron Pharmaceuticals Price Performance

REGN traded down $12.50 on Tuesday, hitting $1,044.52. 259,807 shares of the stock were exchanged, compared to its average volume of 477,710. Regeneron Pharmaceuticals, Inc. has a 12 month low of $688.52 and a 12 month high of $1,081.17. The business has a 50-day moving average of $987.40 and a two-hundred day moving average of $952.81. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The firm has a market capitalization of $115.10 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 2.17 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Eudaimonia Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 11 shares during the period. Team Hewins LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares in the last quarter. Angeles Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 11 shares in the last quarter. Drive Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares in the last quarter. Finally, MCF Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,027.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.